TNX-102 SL Advances Toward Phase 2 Depression Research; Tonix Pharma Sets HORIZON Trial for Mid-2026

Major Depressive Disorder impacts over 21 million American adults annually, with existing antidepressant treatments frequently falling short or causing intolerable side effects. This gap in therapeutic options has prompted ongoing research into alternative mechanisms of action. Tonix Pharmaceuticals Holding Corp. (TNXP) has now obtained FDA authorization to progress its investigational candidate TNX-102 SL into a pivotal Phase 2 clinical program targeting this indication.

Drug Profile and Clinical Rationale

TNX-102 SL is a proprietary sublingual formulation of cyclobenzaprine hydrochloride, specifically engineered to address sleep disruption commonly seen in depressed patients. The compound received FDA approval in August 2024 for fibromyalgia treatment under the TONMYA brand name. Preliminary evidence from fibromyalgia and PTSD symbol studies suggested measurable improvements in depressive symptomatology, establishing the scientific foundation for the current MDD investigation.

HORIZON Trial Design and Timeline

The planned study, designated HORIZON, represents a potential pivotal examination utilizing a six-week, randomized, double-blind, placebo-controlled architecture. The trial will recruit approximately 360 adults with moderate-to-severe Major Depressive Disorder across roughly 30 clinical sites in the United States. Initiation is anticipated during mid-2026.

Researchers will measure primary efficacy through changes in Montgomery-Asberg Depression Rating Scale (MADRS) scores from baseline to Week 6. Secondary assessments include clinical global impression evaluations, anxiety symptom tracking, sleep quality metrics, and Beck Depression Inventory-II (BDI-II) scores.

Safety Profile and Pipeline Context

Early clinical data indicate TNX-102 SL demonstrates favorable tolerability, with reduced incidence of adverse events typically associated with conventional antidepressants. The broader Tonix pipeline encompasses research programs in PTSD, Long COVID, alcohol use disorder, Alzheimer’s-related agitation, and infectious disease applications, supported by patent exclusivity extending through 2034, with potential extension to 2044 via method-of-use claims.

Market Position

TNXP stock has fluctuated between $6.76 and $130 over the preceding twelve months. Current pre-market trading reflects activity at $15.77, representing a 2.05% decrease from prior close.